中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial

文献类型：期刊论文

作者Zhao, Lingzhou1; Xing, Yan1; Liu, Changcun1; Ma, Shaofei2; Huang, Wenhua3; Cheng, Zhen4,5; Zhao, Jinhua1
刊名BREAST CANCER RESEARCH
出版日期2024-03-08
卷号26期号:1页码:40
关键词HER2 Breast cancer Nanobody SPECT/CT imaging Tc-99m
DOI10.1186/s13058-024-01803-y
文献子类Article
英文摘要Background Tc-99m radiolabeled nanobody NM-02 (Tc-99m-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between Tc-99m-NM-02 uptake and HER2 expression in patients with breast cancer. Methods Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both Tc-99m-NM-02 SPECT/computed tomography (CT) and F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUVmax) of F-18-FDG and SUVmax and mean SUV (SUVmean) of Tc-99m-NM-02 in the lesions were determined to analyze the relationship with HER2 expression. Results No meaningful relationship was observed between F-18-FDG uptake and HER2 expression in 30 patients with breast cancer. Tc-99m-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. Tc-99m-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. Tc-99m-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from F-18-FDG PET/CT. Tc-99m-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer. Conclusions Tc-99m-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.
WOS关键词PET/CT ; TOOL
WOS研究方向Oncology
语种英语
WOS记录号WOS:001181362600001
出版者BMC
源URL[http://119.78.100.183/handle/2S10ELR8/317006]  
专题新药研究国家重点实验室
通讯作者Cheng, Zhen; Zhao, Jinhua
作者单位1.Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Nucl Med, 100 Haining Rd, Shanghai 200080, Peoples R China;
2.Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Pathol, 100 Haining Rd, Shanghai 200080, Peoples R China;
3.Nanomab Technol Ltd, 333 North Chengdu Rd, Shanghai 200041, Peoples R China;
4.Chinese Acad Sci, Shanghai Inst Mat Med, Mol Imaging Ctr, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China;
5.Bohai Rim Adv Res Inst Drug Discovery, Shandong Lab Yantai Drug Discovery, 198 Binhai East Rd, Yantai 264000, Shandong, Peoples R China
推荐引用方式
GB/T 7714		 Zhao, Lingzhou,Xing, Yan,Liu, Changcun,et al. Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial[J]. BREAST CANCER RESEARCH,2024,26(1):40.
APA Zhao, Lingzhou.,Xing, Yan.,Liu, Changcun.,Ma, Shaofei.,Huang, Wenhua.,...&Zhao, Jinhua.(2024).Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.BREAST CANCER RESEARCH,26(1),40.
MLA Zhao, Lingzhou,et al."Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial".BREAST CANCER RESEARCH 26.1(2024):40.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。